NERV [NASD]
Minerva Neurosciences, Inc.
Index- P/E- EPS (ttm)-9.53 Insider Own3.42% Shs Outstand5.34M Perf Week13.25%
Market Cap17.56M Forward P/E- EPS next Y-6.92 Insider Trans0.00% Shs Float5.16M Perf Month754.76%
Income-50.90M PEG- EPS next Q-1.65 Inst Own46.30% Short Float0.61% Perf Quarter332.43%
Sales- P/S- EPS this Y21.40% Inst Trans-5.59% Short Ratio0.21 Perf Half Y331.96%
Book/sh-0.14 P/B- EPS next Y12.00% ROA-58.00% Target Price53.33 Perf Year53.42%
Cash/sh- P/C- EPS next 5Y- ROE-284.60% 52W Range0.33 - 3.69 Perf YTD348.19%
Dividend- P/FCF- EPS past 5Y-3.50% ROI- 52W High-2.62% Beta1.12
Dividend %- Quick Ratio17.10 Sales past 5Y- Gross Margin- 52W Low994.90% ATR0.27
Employees9 Current Ratio17.10 Sales Q/Q- Oper. Margin- RSI (14)88.75 Volatility8.24% 12.63%
OptionableYes Debt/Eq- EPS Q/Q-10.90% Profit Margin- Rel Volume0.21 Prev Close3.31
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume151.54K Price3.59
Recom2.00 SMA20139.95% SMA50308.39% SMA200262.35% Volume31,337 Change8.46%
Jun-08-20Reiterated H.C. Wainwright Buy $20 → $10
May-14-20Initiated BTIG Research Buy $23
Oct-02-19Reiterated Chardan Capital Markets Buy $17
Sep-25-19Initiated Chardan Capital Markets Buy $17
Sep-18-19Initiated William Blair Outperform
May-31-19Initiated H.C. Wainwright Buy
Sep-01-17Initiated Citigroup Buy $11
Mar-06-17Resumed Jefferies Buy $17
May-12-16Resumed Jefferies Buy
Jun-22-22 08:58AM  
May-04-22 08:30AM  
Apr-07-22 09:57AM  
08:30AM  
Mar-21-22 09:52AM  
Mar-01-22 09:05AM  
07:30AM  
Feb-28-22 08:30AM  
Dec-01-21 07:44AM  
Nov-08-21 08:45AM  
07:30AM  
Nov-03-21 08:30AM  
Nov-01-21 08:30AM  
Oct-11-21 08:30AM  
Oct-01-21 07:00AM  
Sep-30-21 10:32AM  
08:30AM  
Sep-27-21 08:30AM  
Sep-08-21 08:30AM  
Aug-02-21 08:55AM  
07:30AM  
Jul-26-21 03:01PM  
08:30AM  
Jun-10-21 08:30AM  
Jun-04-21 05:20AM  
May-28-21 08:00AM  
May-19-21 06:19AM  
May-17-21 07:57AM  
May-13-21 09:01AM  
May-12-21 02:35PM  
10:03AM  
08:30AM  
07:30AM  
07:20AM  
06:59AM  
06:45AM  
May-11-21 04:15PM  
May-05-21 05:10PM  
Apr-07-21 08:46AM  
Apr-05-21 09:31AM  
Mar-08-21 12:30PM  
07:30AM  
05:30AM  
Mar-06-21 10:57AM  
Mar-01-21 08:30AM  
Feb-08-21 02:30PM  
01:20PM  
12:30PM  
11:30AM  
11:13AM  
11:00AM  
09:43AM  
06:20AM  
12:45AM  
Feb-07-21 01:12PM  
10:30AM  
Feb-06-21 01:10PM  
10:00AM  
07:15AM  
Feb-05-21 09:15PM  
09:00PM  
07:00PM  
04:35PM  
04:00PM  
01:00PM  
12:15PM  
11:45AM  
11:00AM  
10:35AM  
09:39AM  
Feb-04-21 02:00PM  
12:30PM  
12:28PM  
11:00AM  
06:25AM  
Feb-03-21 10:20PM  
09:00PM  
07:00PM  
05:30PM  
04:23PM  
03:15PM  
02:30PM  
01:45PM  
12:32PM  
11:00AM  
06:07AM  
Feb-02-21 11:28PM  
01:40PM  
01:00PM  
12:05PM  
11:00AM  
11:00AM  
09:05AM  
08:00AM  
03:23AM  
Feb-01-21 04:50PM  
04:00PM  
Jan-31-21 10:20AM  
05:05AM  
05:00AM  
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kupfer DavidDirectorDec 01Sale0.8855,63548,959163,553Dec 03 05:37 PM